Navigation Links
Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board
Date:4/20/2009

Renowned Physicians Join World Class Group of Advisors

SAN DIEGO, April 20 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the expansion of its Clinical Advisory Board, naming Donald H. Batts, MD, FACP, FIDSA, and G. Ralph Corey, MD, as the sixth and seventh members of the group of anti-infective thought leaders. Dr. Batts is a Professor of Medicine at Michigan State University and the Chief of Infectious Diseases at its Kalamazoo Campus. Dr. Corey is the Gary Hock Distinguished Professor of Global Health and the Director of the Hubert/Yeargan Center for Global Health and Director of Infectious Disease Research at the Duke Clinical Research Institute.

"Don and Ralph bring years of academic and industry experience to the Advisory Board that will benefit us as we advance torezolid into Phase 3 development," said Philippe Prokocimer, MD, Chief Medical Officer of Trius. "Collectively, their clinical development of anti-infectives has contributed to the approval of several important new drugs."

"Torezolid is one of the most compelling antibacterial drugs in the clinic so I look forward to advising Trius on its continued development," said Dr. Batts, who was lead investigator at the Upjohn Company for the development of linezolid, the sole marketed antibiotic in the oxazolidinone class.

"I look forward to working closely with Dr. Prokocimer and the rest of the Trius team to help develop the clinical and regulatory strategy for torezolid as it moves into Phase 3 testing," said Dr. Corey.

"The guidance that these distinguished clinicians provide will be critical not only for torezolid as it transitions into Phase 3 testing, but also for our preclinical programs as we advance them toward Phase 1 testing," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "Our goal is to provide patients and physicians best-in-class therapeutic options to address the growing unmet need for safe and effective treatments for drug resistant bacterial infections in the hospital and in the community."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has licensed worldwide rights outside of Korea to torezolid from Dong-A Pharmaceuticals. Trius' pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Trius Awarded $28 Million Contract to Develop Novel Antibiotics
2. Trius Appoints Paul Truex to Board of Directors
3. Ventus Medical Appoints John McCutcheon as President and CEO
4. Sinobiopharma, Inc. Appoints New Director of Marketing
5. Yongye Biotechnology Appoints New Chief Financial Officer
6. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
7. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
8. BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer
9. MacroGenics Appoints New Vice President of Business Development
10. DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors
11. DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... , ... May 23, 2017 ... ... an unlimited source of human cardiovascular cells for research and the development ... makes it possible to generate large numbers of cardiomyocytes (hPSC-CMs). Due to ...
(Date:5/23/2017)... ... May 23, 2017 , ... Vortex Biosciences , provider of circulating ... prostate circulating tumor cells using Vortex microfluidic technology ” in Nature Precision Oncology on ... Dr. Dino Di Carlo and Dr. Matthew Rettig at the University of California, Los ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge Semantics , the ... this year’s Bio-IT World Conference and Expo in Boston May 23-25 with ... solution. The Anzo Smart Data Lake is also a finalist for the Best ...
(Date:5/22/2017)... ... May 22, 2017 , ... Cancer ... exhibiting in booth B2 at the Association for Pathology Informatics Annual Summit ... In addition to demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will ...
Breaking Biology Technology:
(Date:3/23/2017)... -- The report "Gesture Recognition and Touchless Sensing Market by Technology ... Forecast to 2022", published by MarketsandMarkets, the market is expected to be worth ... and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... , March 21, 2017 Vigilant Solutions ... serving law enforcement agencies, announced today the appointment of ... director of public safety business development. Mr. ... enforcement experience, including a focus on the aviation transportation ... most recent position, Mr. Sheridan served as the Aviation ...
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric Face ... ... DERMALOGs Face Matching enables to match face pictures against ... basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching ...
Breaking Biology News(10 mins):